New Medicare Negotiation List Spotlights Small Molecule Liability For Cancer Drugs
The process will pit breast cancer treatment competitors Kisqali and Verzenio against each other as CMS develops pricing offers.
Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972
Outlook 2026 is live!
See the latest industry league tables, and read exclusive industry analysis and C-suite interviews.
Drug Pricing Developments
Interviews
Focus On Asia
India’s Innovation Leap: Biofoundry Network, Public-Private AI Research And More Actioned
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Data Analysis
Podcasts
Pink Sheet Podcast
Scrip Podcast
HBW Insight Podcast
In Vivo Podcast
R&D
• By
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
• By
Attention now shifts to the company’s review of unblinded data and whether changes to patient enrolment could support further evaluation.
• By
Boehringer Ingelheim hopes TPRC6 inhibition can provide a disease-modifying therapy for focal segmental glomerulosclerosis, which has no approved therapy. The smallest dose used in its Phase II study showed the highest response rate.
• By
The Swiss company’s strategy head, Ronny Gal, joins calls for improvement in US competitiveness, as McKinsey highlights competition from other Asian countries beyond China.
Business
• By
Paul Hudson has acknowledged the firm’s R&D setbacks but says they are par for the course when tackling science ‘that has never been done before.’
• By
CEO Thomas Schinecker is signalling that historic investment in Switzerland cannot be sustained unless the country makes its investment and pricing environment more pharma-friendly.
• By
While China is already a key market for AstraZeneca, the UK-based firm has announced a $15bn investment commitment in the country to boost its capabilities in cell therapy and radioconjugates.
• By
Tenpoint expects to launch its Yuvezzi eye drops in early Q2, where it will compete with other rivals such as LENZ’s Vizz, as well as more traditional options such as glasses and lenses.
Scrip Originals
• By
Plus deals involving Alfasigma/Innovative Molecules, Genethon/AskBio, XTL/NeuroNOS, ESTEVE/TerSera, Tahoe/Alloy, Bayer/Attralus and more.
• By
Despite group sales growth and its pharmaceutical division revenue weathering a big loss of exclusivity, J&J experienced stock price weakness after its fourth-quarter results announcement as geopolitical tensions depressed stock markets again.
• By
Private Company Edition: Twenty eight biopharma firms announced $2.11bn in new VC funding between Jan. 8 and 22 on top of $1.36bn in pre-J.P. Morgan disclosures on Jan. 7 and 8. Corxel led the recent financings with a $287m series D1 round to advance its oral GLP-1 agonist.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.